Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367921 | 0.89 | FGFR4 (0.75) | FGFR4MAPK3FGFR1FGFR2FGFR3 | |
| SCHEMBL16072052 | 0.84 | FGFR4 (0.69) | FGFR4MAPK3FGFR1FGFR2FGFR3 | |
| SCHEMBL24690432 | 0.81 | FGFR4 (0.69) | FGFR4MAPK3FGFR1FGFR2FGFR3 | |
| SCHEMBL15434011 | 0.77 | FGFR4 (1.00) | FGFR4MAPK3FGFR1FGFR2FGFR3 | |
| SCHEMBL15434030 | 0.75 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3FLT1 | |
| SCHEMBL19507767 | 0.74 | FGFR4 (0.73) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL20682249 | 0.73 | FGFR1 (0.54) | FGFR4MAPK3FGFR1FGFR2FGFR3 | |
| SCHEMBL24690431 | 0.71 | FGFR4 (0.51) | FGFR4MAPK3 | |
| SCHEMBL15938583 | 0.70 | MAPK3 (1.00) | MAPK3EGFR | |
| SCHEMBL16071795 | 0.70 | FGFR4 (1.00) | FGFR4MAPK3FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885MAPK3 494/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.